nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltitrexed—Methotrexate—lymphatic system cancer	0.448	1	CrCtD
Raltitrexed—FPGS—Methotrexate—lymphatic system cancer	0.159	0.739	CbGbCtD
Raltitrexed—Tetrahydrofolic acid—Methotrexate—lymphatic system cancer	0.0592	0.2	CrCrCtD
Raltitrexed—Pralatrexate—Methotrexate—lymphatic system cancer	0.0592	0.2	CrCrCtD
Raltitrexed—Pemetrexed—Methotrexate—lymphatic system cancer	0.0592	0.2	CrCrCtD
Raltitrexed—Folic Acid—Methotrexate—lymphatic system cancer	0.0592	0.2	CrCrCtD
Raltitrexed—Leucovorin—Methotrexate—lymphatic system cancer	0.0592	0.2	CrCrCtD
Raltitrexed—TYMS—Methotrexate—lymphatic system cancer	0.0564	0.261	CbGbCtD
Raltitrexed—Supraventricular tachycardia—Fludarabine—lymphatic system cancer	0.000773	0.0199	CcSEcCtD
Raltitrexed—Extravasation—Teniposide—lymphatic system cancer	0.000661	0.017	CcSEcCtD
Raltitrexed—Febrile neutropenia—Bleomycin—lymphatic system cancer	0.000618	0.0159	CcSEcCtD
Raltitrexed—TYMS—Podofilox—Teniposide—lymphatic system cancer	0.000577	0.4	CbGdCrCtD
Raltitrexed—Febrile neutropenia—Carmustine—lymphatic system cancer	0.000539	0.0139	CcSEcCtD
Raltitrexed—Febrile neutropenia—Vincristine—lymphatic system cancer	0.000515	0.0132	CcSEcCtD
Raltitrexed—Febrile neutropenia—Mitoxantrone—lymphatic system cancer	0.000501	0.0129	CcSEcCtD
Raltitrexed—Sepsis—Teniposide—lymphatic system cancer	0.0005	0.0129	CcSEcCtD
Raltitrexed—Extravasation—Bleomycin—lymphatic system cancer	0.000426	0.011	CcSEcCtD
Raltitrexed—Necrosis—Carmustine—lymphatic system cancer	0.000413	0.0106	CcSEcCtD
Raltitrexed—Hepatic failure—Fludarabine—lymphatic system cancer	0.000409	0.0105	CcSEcCtD
Raltitrexed—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.000406	0.0104	CcSEcCtD
Raltitrexed—Necrosis—Mitoxantrone—lymphatic system cancer	0.000384	0.00989	CcSEcCtD
Raltitrexed—Extravasation—Carmustine—lymphatic system cancer	0.000372	0.00957	CcSEcCtD
Raltitrexed—Extravasation—Vincristine—lymphatic system cancer	0.000355	0.00913	CcSEcCtD
Raltitrexed—Skin exfoliation—Bleomycin—lymphatic system cancer	0.000355	0.00913	CcSEcCtD
Raltitrexed—Alopecia—Mechlorethamine—lymphatic system cancer	0.000347	0.00893	CcSEcCtD
Raltitrexed—Extravasation—Mitoxantrone—lymphatic system cancer	0.000346	0.0089	CcSEcCtD
Raltitrexed—TYMS—Vinorelbine—Vincristine—lymphatic system cancer	0.000344	0.238	CbGdCrCtD
Raltitrexed—Dehydration—Fludarabine—lymphatic system cancer	0.000342	0.00881	CcSEcCtD
Raltitrexed—Neutropenia—Teniposide—lymphatic system cancer	0.000338	0.00871	CcSEcCtD
Raltitrexed—Stomatitis—Teniposide—lymphatic system cancer	0.000314	0.00809	CcSEcCtD
Raltitrexed—Skin exfoliation—Carmustine—lymphatic system cancer	0.00031	0.00797	CcSEcCtD
Raltitrexed—Sweating—Teniposide—lymphatic system cancer	0.000309	0.00796	CcSEcCtD
Raltitrexed—Leukopenia—Mechlorethamine—lymphatic system cancer	0.000306	0.00788	CcSEcCtD
Raltitrexed—Neutropenia—Fludarabine—lymphatic system cancer	0.000297	0.00765	CcSEcCtD
Raltitrexed—Sepsis—Carmustine—lymphatic system cancer	0.000281	0.00724	CcSEcCtD
Raltitrexed—Mouth ulceration—Vincristine—lymphatic system cancer	0.00028	0.00721	CcSEcCtD
Raltitrexed—Renal failure—Fludarabine—lymphatic system cancer	0.000279	0.00717	CcSEcCtD
Raltitrexed—Infection—Mechlorethamine—lymphatic system cancer	0.000277	0.00714	CcSEcCtD
Raltitrexed—Stomatitis—Fludarabine—lymphatic system cancer	0.000276	0.00711	CcSEcCtD
Raltitrexed—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.000273	0.00703	CcSEcCtD
Raltitrexed—Anorexia—Mechlorethamine—lymphatic system cancer	0.000266	0.00685	CcSEcCtD
Raltitrexed—Sepsis—Mitoxantrone—lymphatic system cancer	0.000262	0.00674	CcSEcCtD
Raltitrexed—Arrhythmia—Teniposide—lymphatic system cancer	0.000259	0.00666	CcSEcCtD
Raltitrexed—Alopecia—Teniposide—lymphatic system cancer	0.000256	0.00659	CcSEcCtD
Raltitrexed—Hepatic failure—Vincristine—lymphatic system cancer	0.00025	0.00644	CcSEcCtD
Raltitrexed—Febrile neutropenia—Methotrexate—lymphatic system cancer	0.00025	0.00643	CcSEcCtD
Raltitrexed—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.000243	0.00624	CcSEcCtD
Raltitrexed—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.000241	0.00621	CcSEcCtD
Raltitrexed—TYMS—Vinblastine—Vincristine—lymphatic system cancer	0.000236	0.164	CbGdCrCtD
Raltitrexed—Anaemia—Teniposide—lymphatic system cancer	0.000233	0.006	CcSEcCtD
Raltitrexed—Arrhythmia—Fludarabine—lymphatic system cancer	0.000227	0.00585	CcSEcCtD
Raltitrexed—Leukopenia—Teniposide—lymphatic system cancer	0.000226	0.00581	CcSEcCtD
Raltitrexed—Alopecia—Fludarabine—lymphatic system cancer	0.000225	0.00579	CcSEcCtD
Raltitrexed—Weight decreased—Bleomycin—lymphatic system cancer	0.000211	0.00543	CcSEcCtD
Raltitrexed—Dehydration—Vincristine—lymphatic system cancer	0.000209	0.00538	CcSEcCtD
Raltitrexed—Oedema—Teniposide—lymphatic system cancer	0.000206	0.0053	CcSEcCtD
Raltitrexed—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.000206	0.00529	CcSEcCtD
Raltitrexed—Anaemia—Fludarabine—lymphatic system cancer	0.000205	0.00527	CcSEcCtD
Raltitrexed—Infection—Teniposide—lymphatic system cancer	0.000204	0.00526	CcSEcCtD
Raltitrexed—Dehydration—Mitoxantrone—lymphatic system cancer	0.000204	0.00524	CcSEcCtD
Raltitrexed—Stomatitis—Bleomycin—lymphatic system cancer	0.000203	0.00522	CcSEcCtD
Raltitrexed—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000201	0.00518	CcSEcCtD
Raltitrexed—Malaise—Fludarabine—lymphatic system cancer	0.0002	0.00514	CcSEcCtD
Raltitrexed—Hyperhidrosis—Teniposide—lymphatic system cancer	0.000199	0.00512	CcSEcCtD
Raltitrexed—Leukopenia—Fludarabine—lymphatic system cancer	0.000198	0.0051	CcSEcCtD
Raltitrexed—Pruritus—Mechlorethamine—lymphatic system cancer	0.000197	0.00508	CcSEcCtD
Raltitrexed—Anorexia—Teniposide—lymphatic system cancer	0.000196	0.00505	CcSEcCtD
Raltitrexed—Cough—Fludarabine—lymphatic system cancer	0.000193	0.00498	CcSEcCtD
Raltitrexed—Necrosis—Methotrexate—lymphatic system cancer	0.000191	0.00493	CcSEcCtD
Raltitrexed—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000191	0.00491	CcSEcCtD
Raltitrexed—Neutropenia—Carmustine—lymphatic system cancer	0.00019	0.0049	CcSEcCtD
Raltitrexed—Arthralgia—Fludarabine—lymphatic system cancer	0.000189	0.00485	CcSEcCtD
Raltitrexed—Discomfort—Fludarabine—lymphatic system cancer	0.000186	0.0048	CcSEcCtD
Raltitrexed—Neutropenia—Vincristine—lymphatic system cancer	0.000182	0.00468	CcSEcCtD
Raltitrexed—Oedema—Fludarabine—lymphatic system cancer	0.000181	0.00465	CcSEcCtD
Raltitrexed—Infection—Fludarabine—lymphatic system cancer	0.00018	0.00462	CcSEcCtD
Raltitrexed—Decreased appetite—Teniposide—lymphatic system cancer	0.000179	0.0046	CcSEcCtD
Raltitrexed—Renal failure—Carmustine—lymphatic system cancer	0.000178	0.00459	CcSEcCtD
Raltitrexed—Vomiting—Mechlorethamine—lymphatic system cancer	0.000177	0.00457	CcSEcCtD
Raltitrexed—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000177	0.00456	CcSEcCtD
Raltitrexed—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000177	0.00455	CcSEcCtD
Raltitrexed—Stomatitis—Carmustine—lymphatic system cancer	0.000177	0.00455	CcSEcCtD
Raltitrexed—Rash—Mechlorethamine—lymphatic system cancer	0.000176	0.00453	CcSEcCtD
Raltitrexed—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000176	0.00452	CcSEcCtD
Raltitrexed—Weight decreased—Vincristine—lymphatic system cancer	0.000176	0.00452	CcSEcCtD
Raltitrexed—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000175	0.0045	CcSEcCtD
Raltitrexed—Anorexia—Fludarabine—lymphatic system cancer	0.000172	0.00444	CcSEcCtD
Raltitrexed—Extravasation—Methotrexate—lymphatic system cancer	0.000172	0.00443	CcSEcCtD
Raltitrexed—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000171	0.00441	CcSEcCtD
Raltitrexed—Feeling abnormal—Teniposide—lymphatic system cancer	0.00017	0.00436	CcSEcCtD
Raltitrexed—Stomatitis—Vincristine—lymphatic system cancer	0.000169	0.00435	CcSEcCtD
Raltitrexed—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000168	0.00433	CcSEcCtD
Raltitrexed—Sweating—Vincristine—lymphatic system cancer	0.000166	0.00427	CcSEcCtD
Raltitrexed—Renal failure—Mitoxantrone—lymphatic system cancer	0.000166	0.00427	CcSEcCtD
Raltitrexed—Nausea—Mechlorethamine—lymphatic system cancer	0.000166	0.00427	CcSEcCtD
Raltitrexed—Alopecia—Bleomycin—lymphatic system cancer	0.000165	0.00424	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000165	0.00424	CcSEcCtD
Raltitrexed—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000164	0.00423	CcSEcCtD
Raltitrexed—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.000164	0.00422	CcSEcCtD
Raltitrexed—Body temperature increased—Teniposide—lymphatic system cancer	0.000163	0.00419	CcSEcCtD
Raltitrexed—Abdominal pain—Teniposide—lymphatic system cancer	0.000163	0.00419	CcSEcCtD
Raltitrexed—Sweating—Mitoxantrone—lymphatic system cancer	0.000162	0.00416	CcSEcCtD
Raltitrexed—Dyspepsia—Fludarabine—lymphatic system cancer	0.000159	0.0041	CcSEcCtD
Raltitrexed—Decreased appetite—Fludarabine—lymphatic system cancer	0.000157	0.00405	CcSEcCtD
Raltitrexed—Constipation—Fludarabine—lymphatic system cancer	0.000155	0.00398	CcSEcCtD
Raltitrexed—Pain—Fludarabine—lymphatic system cancer	0.000155	0.00398	CcSEcCtD
Raltitrexed—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000151	0.00388	CcSEcCtD
Raltitrexed—Anaemia—Bleomycin—lymphatic system cancer	0.00015	0.00386	CcSEcCtD
Raltitrexed—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000149	0.00384	CcSEcCtD
Raltitrexed—Asthenia—Teniposide—lymphatic system cancer	0.000148	0.0038	CcSEcCtD
Raltitrexed—TYMS—Azacitidine—Fludarabine—lymphatic system cancer	0.000147	0.102	CbGdCrCtD
Raltitrexed—Malaise—Bleomycin—lymphatic system cancer	0.000146	0.00377	CcSEcCtD
Raltitrexed—Pruritus—Teniposide—lymphatic system cancer	0.000146	0.00375	CcSEcCtD
Raltitrexed—Arrhythmia—Carmustine—lymphatic system cancer	0.000145	0.00375	CcSEcCtD
Raltitrexed—Leukopenia—Bleomycin—lymphatic system cancer	0.000145	0.00374	CcSEcCtD
Raltitrexed—Alopecia—Carmustine—lymphatic system cancer	0.000144	0.0037	CcSEcCtD
Raltitrexed—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000143	0.00369	CcSEcCtD
Raltitrexed—Body temperature increased—Fludarabine—lymphatic system cancer	0.000143	0.00368	CcSEcCtD
Raltitrexed—Cough—Bleomycin—lymphatic system cancer	0.000142	0.00365	CcSEcCtD
Raltitrexed—Diarrhoea—Teniposide—lymphatic system cancer	0.000141	0.00362	CcSEcCtD
Raltitrexed—TYMS—Azacitidine—Cytarabine—lymphatic system cancer	0.000138	0.096	CbGdCrCtD
Raltitrexed—Alopecia—Vincristine—lymphatic system cancer	0.000137	0.00354	CcSEcCtD
Raltitrexed—Discomfort—Bleomycin—lymphatic system cancer	0.000137	0.00352	CcSEcCtD
Raltitrexed—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000136	0.0035	CcSEcCtD
Raltitrexed—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000135	0.00348	CcSEcCtD
Raltitrexed—Alopecia—Mitoxantrone—lymphatic system cancer	0.000134	0.00344	CcSEcCtD
Raltitrexed—Oedema—Bleomycin—lymphatic system cancer	0.000133	0.00341	CcSEcCtD
Raltitrexed—Infection—Bleomycin—lymphatic system cancer	0.000132	0.00339	CcSEcCtD
Raltitrexed—Anaemia—Carmustine—lymphatic system cancer	0.000131	0.00337	CcSEcCtD
Raltitrexed—Vomiting—Teniposide—lymphatic system cancer	0.000131	0.00337	CcSEcCtD
Raltitrexed—Sepsis—Methotrexate—lymphatic system cancer	0.00013	0.00336	CcSEcCtD
Raltitrexed—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00013	0.00334	CcSEcCtD
Raltitrexed—Asthenia—Fludarabine—lymphatic system cancer	0.00013	0.00334	CcSEcCtD
Raltitrexed—Rash—Teniposide—lymphatic system cancer	0.00013	0.00334	CcSEcCtD
Raltitrexed—Dermatitis—Teniposide—lymphatic system cancer	0.00013	0.00334	CcSEcCtD
Raltitrexed—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000129	0.00332	CcSEcCtD
Raltitrexed—Headache—Teniposide—lymphatic system cancer	0.000129	0.00332	CcSEcCtD
Raltitrexed—Pruritus—Fludarabine—lymphatic system cancer	0.000128	0.00329	CcSEcCtD
Raltitrexed—Leukopenia—Carmustine—lymphatic system cancer	0.000127	0.00327	CcSEcCtD
Raltitrexed—Anorexia—Bleomycin—lymphatic system cancer	0.000126	0.00325	CcSEcCtD
Raltitrexed—Anaemia—Vincristine—lymphatic system cancer	0.000125	0.00322	CcSEcCtD
Raltitrexed—Diarrhoea—Fludarabine—lymphatic system cancer	0.000124	0.00318	CcSEcCtD
Raltitrexed—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000122	0.00315	CcSEcCtD
Raltitrexed—Nausea—Teniposide—lymphatic system cancer	0.000122	0.00315	CcSEcCtD
Raltitrexed—Anaemia—Mitoxantrone—lymphatic system cancer	0.000122	0.00314	CcSEcCtD
Raltitrexed—Hepatic failure—Methotrexate—lymphatic system cancer	0.000121	0.00312	CcSEcCtD
Raltitrexed—Leukopenia—Vincristine—lymphatic system cancer	0.000121	0.00312	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000121	0.00311	CcSEcCtD
Raltitrexed—Malaise—Mitoxantrone—lymphatic system cancer	0.000119	0.00306	CcSEcCtD
Raltitrexed—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000118	0.00304	CcSEcCtD
Raltitrexed—Oedema—Carmustine—lymphatic system cancer	0.000116	0.00298	CcSEcCtD
Raltitrexed—Decreased appetite—Bleomycin—lymphatic system cancer	0.000115	0.00297	CcSEcCtD
Raltitrexed—Cough—Mitoxantrone—lymphatic system cancer	0.000115	0.00296	CcSEcCtD
Raltitrexed—Infection—Carmustine—lymphatic system cancer	0.000115	0.00296	CcSEcCtD
Raltitrexed—Vomiting—Fludarabine—lymphatic system cancer	0.000115	0.00296	CcSEcCtD
Raltitrexed—Rash—Fludarabine—lymphatic system cancer	0.000114	0.00293	CcSEcCtD
Raltitrexed—Dermatitis—Fludarabine—lymphatic system cancer	0.000114	0.00293	CcSEcCtD
Raltitrexed—Pain—Bleomycin—lymphatic system cancer	0.000113	0.00292	CcSEcCtD
Raltitrexed—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000113	0.00292	CcSEcCtD
Raltitrexed—Headache—Fludarabine—lymphatic system cancer	0.000113	0.00292	CcSEcCtD
Raltitrexed—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000112	0.00289	CcSEcCtD
Raltitrexed—Discomfort—Mitoxantrone—lymphatic system cancer	0.000111	0.00285	CcSEcCtD
Raltitrexed—Oedema—Vincristine—lymphatic system cancer	0.00011	0.00284	CcSEcCtD
Raltitrexed—Anorexia—Carmustine—lymphatic system cancer	0.00011	0.00284	CcSEcCtD
Raltitrexed—Infection—Vincristine—lymphatic system cancer	0.00011	0.00282	CcSEcCtD
Raltitrexed—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000109	0.00281	CcSEcCtD
Raltitrexed—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000108	0.00278	CcSEcCtD
Raltitrexed—Oedema—Mitoxantrone—lymphatic system cancer	0.000108	0.00277	CcSEcCtD
Raltitrexed—Nausea—Fludarabine—lymphatic system cancer	0.000107	0.00276	CcSEcCtD
Raltitrexed—Infection—Mitoxantrone—lymphatic system cancer	0.000107	0.00275	CcSEcCtD
Raltitrexed—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000107	0.00275	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000105	0.00271	CcSEcCtD
Raltitrexed—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000105	0.00271	CcSEcCtD
Raltitrexed—Anorexia—Vincristine—lymphatic system cancer	0.000105	0.00271	CcSEcCtD
Raltitrexed—Body temperature increased—Bleomycin—lymphatic system cancer	0.000105	0.0027	CcSEcCtD
Raltitrexed—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000104	0.00268	CcSEcCtD
Raltitrexed—Anorexia—Mitoxantrone—lymphatic system cancer	0.000103	0.00264	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000101	0.00259	CcSEcCtD
Raltitrexed—Decreased appetite—Carmustine—lymphatic system cancer	0.000101	0.00259	CcSEcCtD
Raltitrexed—Pain—Carmustine—lymphatic system cancer	9.89e-05	0.00255	CcSEcCtD
Raltitrexed—Constipation—Carmustine—lymphatic system cancer	9.89e-05	0.00255	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	9.8e-05	0.00252	CcSEcCtD
Raltitrexed—Decreased appetite—Vincristine—lymphatic system cancer	9.6e-05	0.00247	CcSEcCtD
Raltitrexed—Feeling abnormal—Carmustine—lymphatic system cancer	9.53e-05	0.00245	CcSEcCtD
Raltitrexed—Asthenia—Bleomycin—lymphatic system cancer	9.51e-05	0.00245	CcSEcCtD
Raltitrexed—Dyspepsia—Mitoxantrone—lymphatic system cancer	9.47e-05	0.00244	CcSEcCtD
Raltitrexed—Gastrointestinal pain—Carmustine—lymphatic system cancer	9.46e-05	0.00244	CcSEcCtD
Raltitrexed—Constipation—Vincristine—lymphatic system cancer	9.44e-05	0.00243	CcSEcCtD
Raltitrexed—Pain—Vincristine—lymphatic system cancer	9.44e-05	0.00243	CcSEcCtD
Raltitrexed—Pruritus—Bleomycin—lymphatic system cancer	9.38e-05	0.00241	CcSEcCtD
Raltitrexed—Decreased appetite—Mitoxantrone—lymphatic system cancer	9.35e-05	0.00241	CcSEcCtD
Raltitrexed—Constipation—Mitoxantrone—lymphatic system cancer	9.2e-05	0.00237	CcSEcCtD
Raltitrexed—Pain—Mitoxantrone—lymphatic system cancer	9.2e-05	0.00237	CcSEcCtD
Raltitrexed—Abdominal pain—Carmustine—lymphatic system cancer	9.15e-05	0.00235	CcSEcCtD
Raltitrexed—Body temperature increased—Carmustine—lymphatic system cancer	9.15e-05	0.00235	CcSEcCtD
Raltitrexed—Gastrointestinal pain—Vincristine—lymphatic system cancer	9.03e-05	0.00233	CcSEcCtD
Raltitrexed—Feeling abnormal—Mitoxantrone—lymphatic system cancer	8.86e-05	0.00228	CcSEcCtD
Raltitrexed—Neutropenia—Methotrexate—lymphatic system cancer	8.81e-05	0.00227	CcSEcCtD
Raltitrexed—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	8.8e-05	0.00226	CcSEcCtD
Raltitrexed—Abdominal pain—Vincristine—lymphatic system cancer	8.73e-05	0.00225	CcSEcCtD
Raltitrexed—Body temperature increased—Vincristine—lymphatic system cancer	8.73e-05	0.00225	CcSEcCtD
Raltitrexed—Abdominal pain—Mitoxantrone—lymphatic system cancer	8.5e-05	0.00219	CcSEcCtD
Raltitrexed—Body temperature increased—Mitoxantrone—lymphatic system cancer	8.5e-05	0.00219	CcSEcCtD
Raltitrexed—Vomiting—Bleomycin—lymphatic system cancer	8.43e-05	0.00217	CcSEcCtD
Raltitrexed—Rash—Bleomycin—lymphatic system cancer	8.36e-05	0.00215	CcSEcCtD
Raltitrexed—Dermatitis—Bleomycin—lymphatic system cancer	8.35e-05	0.00215	CcSEcCtD
Raltitrexed—Asthenia—Carmustine—lymphatic system cancer	8.3e-05	0.00214	CcSEcCtD
Raltitrexed—Renal failure—Methotrexate—lymphatic system cancer	8.26e-05	0.00213	CcSEcCtD
Raltitrexed—Stomatitis—Methotrexate—lymphatic system cancer	8.19e-05	0.00211	CcSEcCtD
Raltitrexed—Conjunctivitis—Methotrexate—lymphatic system cancer	8.17e-05	0.0021	CcSEcCtD
Raltitrexed—Sweating—Methotrexate—lymphatic system cancer	8.06e-05	0.00207	CcSEcCtD
Raltitrexed—Asthenia—Vincristine—lymphatic system cancer	7.92e-05	0.00204	CcSEcCtD
Raltitrexed—Diarrhoea—Carmustine—lymphatic system cancer	7.92e-05	0.00204	CcSEcCtD
Raltitrexed—Nausea—Bleomycin—lymphatic system cancer	7.87e-05	0.00203	CcSEcCtD
Raltitrexed—Asthenia—Mitoxantrone—lymphatic system cancer	7.72e-05	0.00199	CcSEcCtD
Raltitrexed—Diarrhoea—Vincristine—lymphatic system cancer	7.56e-05	0.00195	CcSEcCtD
Raltitrexed—Diarrhoea—Mitoxantrone—lymphatic system cancer	7.36e-05	0.00189	CcSEcCtD
Raltitrexed—Vomiting—Carmustine—lymphatic system cancer	7.36e-05	0.00189	CcSEcCtD
Raltitrexed—Rash—Carmustine—lymphatic system cancer	7.3e-05	0.00188	CcSEcCtD
Raltitrexed—Dermatitis—Carmustine—lymphatic system cancer	7.29e-05	0.00188	CcSEcCtD
Raltitrexed—Headache—Carmustine—lymphatic system cancer	7.25e-05	0.00187	CcSEcCtD
Raltitrexed—Vomiting—Vincristine—lymphatic system cancer	7.02e-05	0.00181	CcSEcCtD
Raltitrexed—Rash—Vincristine—lymphatic system cancer	6.96e-05	0.00179	CcSEcCtD
Raltitrexed—Dermatitis—Vincristine—lymphatic system cancer	6.96e-05	0.00179	CcSEcCtD
Raltitrexed—Headache—Vincristine—lymphatic system cancer	6.92e-05	0.00178	CcSEcCtD
Raltitrexed—Nausea—Carmustine—lymphatic system cancer	6.87e-05	0.00177	CcSEcCtD
Raltitrexed—Vomiting—Mitoxantrone—lymphatic system cancer	6.84e-05	0.00176	CcSEcCtD
Raltitrexed—Rash—Mitoxantrone—lymphatic system cancer	6.78e-05	0.00175	CcSEcCtD
Raltitrexed—Dermatitis—Mitoxantrone—lymphatic system cancer	6.78e-05	0.00174	CcSEcCtD
Raltitrexed—Headache—Mitoxantrone—lymphatic system cancer	6.74e-05	0.00173	CcSEcCtD
Raltitrexed—Alopecia—Methotrexate—lymphatic system cancer	6.67e-05	0.00172	CcSEcCtD
Raltitrexed—Nausea—Vincristine—lymphatic system cancer	6.56e-05	0.00169	CcSEcCtD
Raltitrexed—Dysgeusia—Methotrexate—lymphatic system cancer	6.43e-05	0.00166	CcSEcCtD
Raltitrexed—Nausea—Mitoxantrone—lymphatic system cancer	6.39e-05	0.00164	CcSEcCtD
Raltitrexed—Ill-defined disorder—Methotrexate—lymphatic system cancer	6.09e-05	0.00157	CcSEcCtD
Raltitrexed—Anaemia—Methotrexate—lymphatic system cancer	6.07e-05	0.00156	CcSEcCtD
Raltitrexed—Malaise—Methotrexate—lymphatic system cancer	5.92e-05	0.00152	CcSEcCtD
Raltitrexed—Leukopenia—Methotrexate—lymphatic system cancer	5.88e-05	0.00151	CcSEcCtD
Raltitrexed—Cough—Methotrexate—lymphatic system cancer	5.73e-05	0.00148	CcSEcCtD
Raltitrexed—Arthralgia—Methotrexate—lymphatic system cancer	5.59e-05	0.00144	CcSEcCtD
Raltitrexed—Discomfort—Methotrexate—lymphatic system cancer	5.52e-05	0.00142	CcSEcCtD
Raltitrexed—Infection—Methotrexate—lymphatic system cancer	5.32e-05	0.00137	CcSEcCtD
Raltitrexed—Thrombocytopenia—Methotrexate—lymphatic system cancer	5.25e-05	0.00135	CcSEcCtD
Raltitrexed—Hyperhidrosis—Methotrexate—lymphatic system cancer	5.18e-05	0.00133	CcSEcCtD
Raltitrexed—Anorexia—Methotrexate—lymphatic system cancer	5.11e-05	0.00132	CcSEcCtD
Raltitrexed—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	4.88e-05	0.00126	CcSEcCtD
Raltitrexed—Dyspepsia—Methotrexate—lymphatic system cancer	4.72e-05	0.00121	CcSEcCtD
Raltitrexed—Decreased appetite—Methotrexate—lymphatic system cancer	4.66e-05	0.0012	CcSEcCtD
Raltitrexed—Pain—Methotrexate—lymphatic system cancer	4.58e-05	0.00118	CcSEcCtD
Raltitrexed—Feeling abnormal—Methotrexate—lymphatic system cancer	4.42e-05	0.00114	CcSEcCtD
Raltitrexed—Gastrointestinal pain—Methotrexate—lymphatic system cancer	4.38e-05	0.00113	CcSEcCtD
Raltitrexed—Abdominal pain—Methotrexate—lymphatic system cancer	4.24e-05	0.00109	CcSEcCtD
Raltitrexed—Body temperature increased—Methotrexate—lymphatic system cancer	4.24e-05	0.00109	CcSEcCtD
Raltitrexed—Asthenia—Methotrexate—lymphatic system cancer	3.85e-05	0.00099	CcSEcCtD
Raltitrexed—Pruritus—Methotrexate—lymphatic system cancer	3.79e-05	0.000976	CcSEcCtD
Raltitrexed—Diarrhoea—Methotrexate—lymphatic system cancer	3.67e-05	0.000944	CcSEcCtD
Raltitrexed—Vomiting—Methotrexate—lymphatic system cancer	3.41e-05	0.000877	CcSEcCtD
Raltitrexed—Rash—Methotrexate—lymphatic system cancer	3.38e-05	0.00087	CcSEcCtD
Raltitrexed—Dermatitis—Methotrexate—lymphatic system cancer	3.38e-05	0.000869	CcSEcCtD
Raltitrexed—Headache—Methotrexate—lymphatic system cancer	3.36e-05	0.000864	CcSEcCtD
Raltitrexed—Nausea—Methotrexate—lymphatic system cancer	3.18e-05	0.000819	CcSEcCtD
